a year ago

Mission Therapeutics Secures £25.2M to Advance Mitophagy Therapies

  • Mission Therapeutics, a Cambridge, UK-based clinical-stage biotech company developing therapeutics that enhance mitophagy to promote cell/organ health, raised £25.2M in funding

  • The round was led by existing investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital

  • The company intends to use the funds to accelerate development of its lead drug candidates, MTX325 and MTX652, through clinical trials

  • The company is currently developing two small molecule drugs, MTX652 (peripheral) and MTX325 (targeting the CNS) which, through inhibition of the mitochondrial DUB enzyme USP30, will promote clearance of dysfunctional mitochondria – consequently improving overall cellular health

  • Mission’s USP30 inhibitors MTX652 and MTX325 could potentially be used to treat any disease or condition driven by mitochondrial dysfunction.

      • ProblemHealthcare

      "Dysfunctional mitochondria are significant drivers of disease pathophysiology in various diseases such as acute kidney injury, Parkinson’s Disease, heart failure, Duchenne’s Muscular Dystrophy, IPF, mitochondrial diseases, and Alzheimer’s."

      Solution

      "Inhibiting the mitochondrial DUB enzyme USP30 using small molecule drugs MTX652 and MTX325 to promote clearance of dysfunctional mitochondria, improving overall cellular health and potentially treating diseases driven by mitochondrial dysfunction."

      Covered on